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This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).SUMMARYPodocyte loss is a generalmechanismof glomerular dysfunction that initiates and drives the progression of chronic kidney disease, which
affects 10% of the world population. Here, we evaluate whether the regenerative response to podocyte injury influences chronic kidney
disease outcome. In models of focal segmental glomerulosclerosis performed in inducible transgenic mice where podocytes are tagged,
remission or progression of disease was determined by the amount of regenerated podocytes. When the same model was established in
inducible transgenic mice where renal progenitors are tagged, the disease remitted if renal progenitors successfully differentiated into
podocytes, while it persisted if differentiation was ineffective, resulting in glomerulosclerosis. Treatment with BIO, a GSK3s inhibitor,
significantly increased disease remission by enhancing renal progenitor sensitivity to the differentiation effect of endogenous retinoic
acid. These results establish renal progenitors as critical determinants of glomerular disease outcome and a pharmacological enhance-
ment of their differentiation as a possible therapeutic strategy.INTRODUCTION
Chronic kidney diseases (CKDs) affects 10% of the pop-
ulation and represent a major global health burden (Eck-
ardt et al., 2013). Worldwide, the number of patients
with end-stage renal disease (ESRD) receiving renal
replacement therapy is estimated at more than 1.4
million, with an annual growth rate of 8% (Schieppati
and Remuzzi, 2005). ESRD represents only the tip of the
iceberg; even early-stage CKD is associated with increased
prevalence of numerous disorders and an increased risk of
death.
The course of CKD can be extremely variable. Certain
renal diseases quickly lead to irreversible ESRD. More com-
mon nephropathies do progress less rapidly but still
evolve to ESRD at different rates or can show remission
and even regression, spontaneously or following specific
treatments. Even if pathophysiologic mechanisms of
CKD progression are shared and independent of etiology,
the reasons for this extreme outcome variability, even in
patients affected by the same disorder, remain mostly
unknown.
The majority of CKD originates from the glomerulus,
where the podocyte, a highly differentiated cell represent-
ing the main constituent of the filtration barrier, is the248 Stem Cell Reports j Vol. 5 j 248–263 j August 11, 2015 j ª2015 The Autculprit. Indeed, dysfunction and loss of glomerular podo-
cytes are the driving forces for CKD initiation and progres-
sion (Kriz and LeHir, 2005; Chen and Miner, 2012;
Wiggins, 2007). Clinically, this is evidenced by proteinuria,
and unfortunately, there are no clinical methods to repair
podocyte damage. Podocytes are post-mitotic cells that
typically do not divide but can undergo hypertrophy in
an attempt to cover the underlying glomerular basement
membrane in exposed areas where neighboring cells have
detached or died (Wanner et al., 2014). However, if the
injury exceeds a certain threshold, podocyte hypertrophy
reveals itself to be an unfit strategy over time, as the loss
of podocytes and segmental sclerosis lead to podocyte
detachment and a decreased ultrafiltration capacity (Wig-
gins, 2007; Lasagni et al., 2013). Therefore, the identifica-
tion of effective ways to promote podocyte regeneration
has become a major focus of research.
In recent years, some findings have suggested that renal
progenitor cells (RPCs) may exist in humans and represent
a potential source for podocyte replacement (Romagnani,
2009; Romagnani et al., 2013; Shankland et al., 2014).
In humans, RPCs represent a subset of parietal epithelial
cells (PECs) in the Bowman’s capsule that exhibit func-
tional progenitor features and are characterized by co-
expression of two species-specific markers, CD133 andhors
CD24 (Romagnani et al., 2013; Shankland et al., 2014;
Sagrinati et al., 2006; Ronconi et al., 2009). Studies using
mouse models report the capacity of PECs to differentiate
into podocytes, but only during kidney development
(Berger et al., 2014; Appel et al., 2009). Rather, in certain
conditions, PEC activation can be harmful and drives gen-
eration of hyperplastic intraglomerular cellular lesions
(Smeets et al., 2009), leading to nephron degeneration
(Kriz and LeHir, 2005).
In this study, we hypothesized that the response of RPCs
to podocyte injury may determine the outcome of glomer-
ular disorders and that enhancement of podocyte regener-
ation provided by RPCs may represent a new target for the
treatment of CKD.RESULTS
Remission of Glomerular Disease after Podocyte Injury
Is Associated with the Generation of Novel Podocytes
To test whether the generation of new podocytes after
injury can influence disease outcome, we first used
NPHS2.iCreERT2;mT/mG mice. In this inducible transgenic
model, following tamoxifen administration (Figure 1A),
membrane-targeted GFP genetically labels NPHS2-express-
ing cells (podocytes) green, while all the other kidney cells
are labeled red with TomatoRed (TomRed). However, after
tamoxifen withdrawal, newly generated podocytes will
also be labeled red and can be identified as red cells that
are co-stained with anti-synaptopodin (anti-SYN) or anti-
WT1 antibodies. In healthy mice, 8 days of tamoxifen
administration followed by a washout period of 10 days
resulted in near 100% efficiency and specificity of GFP
expression (96.27% ± 0.64%), as demonstrated by the
virtually complete overlap between GFP-labeled podo-
cytes and podocytes labeled with an anti-SYN blue-conju-
gated antibody (Figure 1B). After tamoxifen washout,
NPHS2.iCreERT2;mT/mG mice received two doxorubicin
injections with a 1-week break in between (Figure 1A)
to induce Adriamycin nephropathy, a model of human
focal segmental glomerulosclerosis (FSGS) (Lee and Har-
ris, 2011), in C57Bl/6 mice (Peired et al., 2013). To
evaluate the occurrence of podocyte regeneration at the
single-mouse level, avoiding the influence of interindi-
vidual variability in the efficiency of Cre recombinase
activation, we performed serial biopsies at day 14 from
the second doxorubicin injection in a group of eight
animals and counted the number of GFP+/SYN+ cells
(pre-existing podocytes) and the number of TomRed+/
SYN+ cells (newly generated podocytes) in glomeruli at
days 14 and 28 from the second doxorubicin injection
in each mouse. Representative images of glomeruli in
the biopsy specimen and kidney of the same mouse areStem Cshown in Figures 1C and 1D. A significant increase of
TomRed+/SYN+ newly generated podocytes was observed
(Figure 1E). Similar results were obtained when the
same biopsies were stained with anti-WT1 antibody and
cells counted as GFP+/WT1+ cells (pre-existing podocytes)
or TomRed+/WT1+ cells (newly generated podocytes;
Figures 1F–1I).
To further evaluate whether podocyte regeneration is
associated with proteinuria remission, we induced Adria-
mycin nephropathy in NPHS2.iCreERT2;mT/mG mice
and monitored the urinary albumin/creatinine ratio for
28 days, starting from the second doxorubicin injection
(day 0). At day 28, on the basis of the proteinuria course,
we divided the mice with persistent proteinuria (increase
or persistence of proteinuria in the nephrotic range at day
28) from animals that underwent proteinuria remission
(reduction of proteinuria of at least 50% of the peak values
at day 28), based on the KDIGO Guidelines (Figure 2A)
(KDIGO, 2012). In mice with persistently nephrotic pro-
teinuria, we observed a statistically significant increase in
blood urea nitrogen (BUN) levels at day 28 in comparison
to both healthy mice and mice with proteinuria remission
(Figure 2B). At day 28, we analyzed kidneys by confocal mi-
croscopy and counted the number of GFP+/SYN+ cells and
the number of TomRed+/SYN+ cells in glomeruli of healthy
mice, mice with persistent proteinuria and CKD, and mice
that underwent proteinuria remission. Representative
images of glomeruli of persistently proteinuric mice and
mice with proteinuria remission stained with an anti-SYN
antibody are shown in Figures 2C and 2D, respectively. In
mice with persistently nephrotic proteinuria, we counted
8.75 ± 0.15 GFP+/SYN+ podocytes and 0.48 ± 0.05
TomRed+/SYN+ podocytes per glomerular section. By
contrast, in mice with proteinuria remission, we observed
8.9 ± 0.23 GFP+/SYN+ podocytes and 0.95 ± 0.06
TomRed+/SYN+ podocytes per glomerular section (Figures
2E and 2F). Only the number of TomRed+/SYN+ podocytes
was significantly different in mice with persistent protein-
uria versus mice with proteinuria remission, suggesting
that the different podocyte number observed at day 28 in
these groups of mice was related to a different amount of
podocyte regeneration. Indeed, once we subtracted the
background of TomRed+/SYN+ cells over total podocytes
present in healthy kidney, the percentage of newly gener-
ated podocytes was 1.43% in mice with persistent protein-
uria and 5.9% in mice with proteinuria remission when
calculated over the total amount of kidney podocytes.
However, since podocyte injury is focal and segmental
and only a limited amount of podocytes is lost, this
corresponds to regeneration of 30.4% of lost podocytes
in mice with proteinuria remission versus only 7.0% in
mice with persistent proteinuria (Figure 2G; see Supple-
mental Experimental Procedures for a detailed descriptionell Reports j Vol. 5 j 248–263 j August 11, 2015 j ª2015 The Authors 249
Figure 1. Podocyte Regeneration Occurs after Podocyte Detachment and Is Not Driven by Mitosis of Pre-existing Podocytes
(A) Experimental scheme.
(B) Healthy kidney from a NPHS2.iCreERT2;mT/mG mouse stained with anti-SYN (blue).
(C and D) Low (top) and high (bottom) magnification of a renal biopsy specimen from a doxorubicin-treated NPHS2.iCreERT2;mT/mGmouse
at day 14 (C) and the kidney of the same mouse at day 28 (D) stained with anti-SYN (blue).
(E) Number of pre-existing podocytes (detected as green and blue cells, GFP+/SYN+) (top) and number of newly generated podocytes
(detected as red and blue cells, TomRed+/SYN+) (bottom) per glomerular section of all glomeruli in the biopsy specimen (day 14) and
kidney (day 28) (n = 8) of each mouse; *p < 0.05 (day 28) by Wilcoxon test.
(F) Healthy kidney from a NPHS2.iCreERT2;mT/mG mouse stained with anti-WT1 (blue).
(G and H) Low (top) and high (bottom) magnification of renal biopsy from a doxorubicin-treated NPHS2.iCreERT2;mT/mG mouse at day 14
(G) and kidney of the same mouse at day 28 (H) stained with anti-WT1 (blue).
(I) Number of pre-existing podocytes (detected as green and blue cells, GFP+/WT1+) (top) and number of newly generated podocytes
(detected as red and blue cells, TomRed+/WT1+) (bottom) per glomerular section of all glomeruli in the biopsy specimen (day 14) and
kidney (day 28) (n = 8) of each mouse; *p < 0.05 (day 28) by Wilcoxon test.
Data represent the mean ± SEM; DAPI counterstains nuclei. Scale bar, 20 mm.of the calculation). Similar results were obtained when the
kidney tissues were stained with an anti-WT1 antibody
(Figures 2H–2J).250 Stem Cell Reports j Vol. 5 j 248–263 j August 11, 2015 j ª2015 The AutTaken together, these results demonstrate that podocyte
regeneration is associatedwithproteinuria remission,while
lack of podocyte regeneration is associated with persistenthors
Figure 2. Remission of Glomerular Disease in Mice with Adriamycin Nephropathy Is Associated with the Generation of Novel
Podocytes
(A) Albumin/creatinine levels in persistent proteinuric NPHS2.iCreERT2;mT/mGmice (n = 10) and mice undergoing remission (n = 5). Day 0
corresponds to the time of second doxorubicin injection; *p < 0.05 (day 28) by Mann-Whitney test.
(B) Blood urea nitrogen levels in healthy (n = 4), progressed (n = 10), and remitted (n = 5) mice at day 28; *p < 0.05 versus healthy mice
and mice with proteinuria remission by Mann-Whitney test.
(C and D) Representative kidney of a NPHS2.iCreERT2;mT/mGmouse with persistent proteinuria (C) and of a NPHS2.iCreERT2;mT/mGmouse
with proteinuria remission (D) stained with anti-SYN (blue).
(E) Number of pre-existing podocytes (detected as green and blue cells, GFP+/SYN+) per glomerular section of all glomeruli in healthy
(n = 4) and persistently proteinuric mice (n = 10) and in mice with proteinuria remission (n = 5) at day 28. *p < 0.05 versus healthy mice by
Mann-Whitney test.
(F) Number of newly generated podocytes (detected as red and blue cells, TomRed+/SYN+) per glomerular section of all glomeruli in
healthy (n = 4) and persistently proteinuric mice (n = 10) and in mice with proteinuria remission (n = 5) at day 28. *p < 0.05 versus healthy
and persistently proteinuric mice by Mann-Whitney test.
(G) Percentage of regenerated podocytes over lost podocytes (n = 10 for proteinuric mice and n = 5 for mice with proteinuria
remission).
(H and I) Representative kidney of a NPHS2.iCreERT2;mT/mGmouse with persistent proteinuria (H) and of a NPHS2.iCreERT2;mT/mGmouse
with proteinuria remission (I) stained with anti-WT1 (blue).
(J) Percentage of regenerated podocytes over lost podocytes (n = 10 for proteinuric mice and n = 5 for mice with proteinuria remission).
Data represent the mean ± SEM; DAPI counterstains nuclei. Scale bar, 20 mm.nephrotic proteinuria and development of CKD. These re-
sults also suggest that newly generated podocytes are
derived not from already existing podocytes but rather
from an unknown podocyte progenitor.Stem CPAX2+ Cells Represent Progenitors that Generate
Novel Podocytes during Kidney Growth
To establish a model for RPC lineage tracing, we decided to
make use of the regulatory region of the transcriptionell Reports j Vol. 5 j 248–263 j August 11, 2015 j ª2015 The Authors 251
Figure 3. PAX2+ Cells Located in Parietal Epithelium of the Bowman’s Capsule Are Progenitors for Podocytes during Postnatal
Kidney Growth
(A) Experimental scheme for results shown in (B) and (C).
(B) Kidney of Pax2.rtTA;TetO.Cre;R26.Confetti mice induced at P5 for 10 days and sacrificed at 2 weeks of age (n = 8). Multicolor Confetti
tracing is shown in red, yellow, and cyan. PAX2+ progenitors are located in parietal epithelium of the Bowman’s capsule and in tubular
structures.
(C) Higher magnification of a glomerulus showing PAX2+ cells only in parietal epithelium of the Bowman’s capsule.
(D) Experimental scheme for results shown in E and F.
(legend continued on next page)
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factor PAX2, a critical regulator of the embryonic progeni-
tor population during kidney development in vertebrates
(Dressler, 2008). PAX2 is co-expressed with CD133 in
RPCs of the adult human kidney (Bussolati et al., 2005;
Ye et al., 2011) and may thus be ideal for lineage tracing
of RPCs of the Bowman’s capsule in the mouse. A trans-
genic Pax2-rtTA mouse strain obtained through genetic re-
combineering using a large bacterial artificial chromosome
(BAC) clone that drives expression of TetO-controlled
transgenes upon doxycycline treatment in natively PAX2-
expressing tissues was previously described and fully vali-
dated (Burger et al., 2011). This mouse was bred with the
Confetti reporter to combine inducible lineage tracing of
PAX2+ cells with clonal analysis (Pax2.rtTA;TetO.Cre;
R26.Confetti; Figure S1A). Indeed, in this reporter, green,
yellow, cyan, or red fluorescent protein is randomly ex-
pressed under the control of the Pax2 promoter, allowing
the tracing of single PAX2-expressing cells and of their
progeny. Since PAX2 can also be expressed by podocyte
precursors during kidney development but is lost upon
their differentiation into mature podocytes and remains
only in the PECs of the Bowman’s capsule in the post-natal
kidney (Ryan et al., 1995), in a preliminary series of exper-
iments, we induced pups with doxycycline through breast-
feeding at different time points and for variable periods of
time after birth. These experiments showed that when dox-
ycyline induction was started at post-natal day 5 (P5) and
went on for 10 days, ending at P14 (Figure 3A), PAX2 was
expressed only by scattered cells within tubular structures
as well as by PECs of the Bowman’s capsule (Figure 3B),
while podocytes were not labeled (Figure 3C). At P5, the
generation of new glomeruli from themetanephric mesen-
chyme (MM) has already ended (Short et al., 2014), but
glomerular shaping up to stage V can continue until P10
(Kazimierczak, 1980). However, when doxycyline is admin-
istered by breastfeeding, at least 5 days of treatment are
needed before Cre recombination occurs in this model,
and during this phase, PAX2 expression in podocytes is
shut off, thus explaining the selectivity of PAX2 labeling
to PECs of the Bowman’s capsule at P14. Since nephron(E) Kidney of Pax2.rtTA;TetO.Cre;R26.Confetti mice induced at P5 for
5 weeks of age (n = 8). Fluorescent cells were present in parietal epi
(F) Higher magnification of a glomerulus showing fluorescently lab
antibody (light blue), demonstrating their differentiation into podoc
(G) Experimental scheme for results shown in (H).
(H) Juxtaposed confocal images from top (outer cortex) to bottom
kidney.
(I) Experimental scheme for results shown in (J) and (K).
(J) Glomeruli with PAX2+ capsule in mice induced at 5 weeks of age fo
following 9 months (n = 6).
(K) Higher magnification of a glomerulus with PAX2+ cells in the Bow
G, glomerulus. DAPI counterstains nuclei (white). Scale bar, 20 mm.
Stem Cdevelopment has already ended at P14 (Hartman et al.,
2007), this represents the optimal starting point to deter-
mine whether PAX2+ PECs contribute to post-natal
glomerular growth. To this aim, in a parallel group of
mice, doxycycline induction was started at P5, and after
10 days of induction, doxycycline was removed at P14,
and mice were chased until the fifth week of age and
then analyzed (Figure 3D). While at P14 virtually no podo-
cytes were labeled, after chasing up to the fifth week of age,
labeled cells were observed not only as PECs of the Bow-
man’s capsule but also inside the glomeruli (0.04 ± 0.03
at P14 versus 0.9 ± 0.16 after chasing up to 5 weeks; p <
0.05; Figure 3E). These intraglomerular PAX2-derived cells
expressed SYN (Figure 3F), demonstrating their podocyte
nature.Whenwe removed doxycycline and started chasing
experiments, only PECs of the Bowman’s capsule exhibited
PAX2 labeling within glomeruli. This excludes the possibil-
ity that the labeled podocytes observed at 5 weeks were
generated during development and demonstrates that
they could only be derived from the PAX2+ PECs present
at P14. Since 11.2 ± 0.5 podocytes are present on average
in each glomerular section of an adult mouse at 5 weeks
of age, this suggests that 8% of podocytes in adult
glomeruli are recruited from PAX2+ cells during postnatal
glomerular growth. These results demonstrate that PAX2+
cells localized within the Bowman’s capsule represent po-
docyte progenitors also once development has ended.
Newly generated podocytes within glomeruli were labeled
with different colors, suggesting they are not the result of
clonal division of a single progenitor and are derived from
migration and differentiation of multiple different progen-
itor cellswithin the same glomerulus (Figures 3E and3F). To
verify the persistence of PAX2+ progenitors in the adult
mouse kidney, animals were then induced at 5 weeks of
age for 10 days and then sacrificed (Figure 3G). No Cre re-
combinase activity was observed in absence of doxycycline
treatment (Figure S1B). We observed PAX2+ cells localized
as PECs in the Bowman’s capsule and scattered within the
tubular structures (Figure 3H). Podocytes were not labeled.
Interestingly, glomeruli with PAX2+ Bowman’s capsules10 days when doxycycline was suspended and mice tracked until
thelium of the Bowman’s capsule as well as inside the glomeruli.
eled PAX2+ cells inside the tuft, positively stained with anti-SYN
ytes.
(inner cortex) of an adult Pax2.rtTA;TetO.Cre;R26.Confetti mouse
r 10 days, then doxycycline was suspended and mice tracked for the
man’s capsule.
See also Figure S1.
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Figure 4. PAX2+ Progenitors Generate Lesions in Mice with Persistent Proteinuria and Podocytes in Animals with Proteinuria
Remission
(A) Experimental scheme.
(B) Albumin/creatinine levels in persistent proteinuric Pax2.rtTA;TetO.Cre;mT/mG mice (n = 11) and mice undergoing remission (n = 5).
Day 0 corresponds to the time of second doxorubicin injection; *p < 0.05 (day 28) by Mann-Whitney test.
(C) Percentage of glomeruli with sclerosis in mice with persistent proteinuria (n = 11) and mice undergoing remission (n = 5). *p < 0.05
versus persistently proteinuric mice (Mann-Whitney test).
(D) Representative periodic acid-Schiff staining of renal sections of persistently proteinuric mice (left) and of mice undergoing remission
(right).
(E and F) Representative glomeruli with PAX2+ capsule in healthy Pax2.rtTA;TetO.Cre;mT/mG mice induced at 5 weeks of age (n = 4).
(legend continued on next page)
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were differently distributed between the different areas of
the cortex (Figure 3H), with a higher presence of positive
glomeruli in the outer cortex in comparison to the inner
cortex (Figure 3H).Onaverage,more than50%of glomeruli
in the outer cortex exhibited PAX2+ cells in the Bowman’s
capsule. No further podocytes were recruited from PAX2+
progenitors from the fifth week up to 10 months of the
life of the animal (Figures 3I–3K).
Taken together, these results demonstrate that Pax2.rtTA;
TetO.Cre;R26.Confetti mice allow specific tracking of RPCs
in the Bowman’s capsule of the mouse kidney.
Remission of Glomerular Disease Depends upon
Differentiation of PAX2 Progenitors into Novel
Podocytes
To evaluate if PAX2+ progenitors could be responsible
for the podocyte regeneration observed in the NPHS2.
iCreERT2;mT/mG model, we induced Adriamycin nephrop-
athy in Pax2.rtTA;TetO.Cre;mT/mG mice (Figure S2A)
following the same protocol used for NPHS2.iCreERT2;mT/
mG mice and shown in Figure 4A. We then monitored uri-
nary albumin/creatinine ratio for 28 days and divided the
mice with persistent proteinuria from those with protein-
uria remission as described above (Figure 4B). At day 28,
mice with persistent proteinuria had an albumin/creati-
nine ratio of 6.7 ± 1.03, whereas the ratio in mice with pro-
teinuria remission was 1.8 ± 0.47 (p < 0.05); animals were
sacrificed and kidneys analyzed. Consistently, mice with
persistent proteinuria showed a higher percentage of
glomeruli with sclerosis in comparison to mice with pro-
teinuria remission (Figures 4C and 4D). In healthy mice,
PAX2+ progenitors were localized exclusively in the PECs
of the Bowman’s capsule (Figures 4E and 4F). In healthy
mice of comparable age that were not treated with doxycy-
cline, no green signal was observed, showing that there was
no transgene leakage (Figure 4G). The green signal was also
absent at day 28 after induction of Adriamycin nephropa-
thy if doxycycline had not been administered, further(G and H) Absence of basal Cre recombinase activity in the kidney
without doxycycline and analyzed at 12 weeks of age (n = 3) (G) and
nephropathy (n = 3) maintained with water without doxycycline and
(I) Representative kidney from a Pax2.rtTA;TetO.Cre;mT/mG mouse w
glomeruli.
(J) Representative kidney from a Pax2.rtTA;TetO.Cre;mT/mG mouse
hyperplastic lesion.
(J0) Higher magnification of (J).
(K) Representative kidney from a Pax2.rtTA;TetO.Cre;mT/mG mouse wi
glomerular tuft.
(K0) Higher magnification of (K).
(L) 3D reconstruction of a glomerulus showing PAX2+ cells in epith
glomerulus.
Data represent the mean ± SEM. DAPI counterstains nuclei (white). S
Stem Cdemonstrating that this system had no leakage, even after
doxorubicin treatment (Figure 4H). By contrast, in mice
treated with doxycycline before induction of Adriamycin
nephropathy, green fluorescent cells could be observed
also inside glomeruli 28 days after injury (Figures 4I–4L).
However, in mice with persistently nephrotic proteinuria,
intraglomerular PAX2-derived green cells were virtually
not detected (Figure 4I) or were observed as components
of adhesions or of hyperplastic intraglomerular lesions
(Figures 4J and 4J0). By contrast, in mice with proteinuria
remission, intraglomerular PAX2+ cells were observed
and localized around capillaries (Figures 4K, 4K0, and 4L)
in virtually normal tufts, and z stack sectioning of
glomeruli showed their continuity with PAX2+ PECs of
the Bowman’s capsule (Figure S2B). Of note, these intraglo-
merular cells derived from PAX2+ PECs showed an arbor-
ized morphology (Figure 4L; Movie S1) suggestive of
podocyte features.
To analyze the phenotypic characteristics of PAX2+ cells
observed within glomeruli of mice with proteinuria
remission, we evaluated the expression of the podocyte
markers podocin (NPHS2), SYN, and WT1. PAX2+ cells
were intensely stained with anti-NPHS2 (Figure 5A),
anti-SYN antibody (Figures 5B–5E), and anti-WT1 anti-
body (Figure 5F). Moreover, these cells showed characteris-
tics of fully differentiated podocytes, presenting foot
processes indistinguishable from resident podocytes (Fig-
ures 5C–5F).
Overall, we counted 0.41 ± 0.07 PAX2+/SYN+ cells per
glomerular section in Pax2.rtTA;TetO.Cre;mT/mG mice
with proteinuria remission, which corresponded to the
regeneration of 24.7% of lost podocytes (Figures 5G and
5H). By contrast, inmice with persistent nephrotic protein-
uria, we observed 0.05 ± 0.01 PAX2+/SYN+ cells per glomer-
ular section, which corresponded to the regeneration of
only 3.3%of lost podocytes (Figures 5G and 5H). Similar re-
sults were obtained when the kidney tissues were stained
with an anti-WT1 antibody (Figure 5H). Thus, on average,of Pax2.rtTA;TetO.Cre;mT/mG healthy mice maintained with water
in the kidney of Pax2.rtTA;TetO.Cre;mT/mG mice with Adriamycin
sacrificed 28 days after the second doxorubicin injection (H).
ith persistent proteinuria. No green cells are present inside the
with persistently nephrotic proteinuria, showing PAX2+ cells in a
th proteinuria remission, where PAX2+ cells are observed inside the
elium of the Bowman’s capsule and PAX2-derived cells inside the
cale bar, 20 mm. See also Figure S2 and Movie S1.
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Figure 5. PAX2+ Progenitors Generate Fully Differentiated Podocytes in Mice with Proteinuria Remission
(A and B) In Pax2.rtTA;TetO.Cre;mT/mG mouse with proteinuria remission, PAX2-derived cells observed inside the glomeruli expressed the
podocyte marker podocin (NPHS2, blue) (A) and SYN (blue) (B).
(B0) Split images of the PAX2+/SYN+ cell inside the glomerulus shown in (B).
(C) Higher magnification of foot processes in the PAX2+/SYN+ cell shown in (B).
(D and E) Higher magnification of PAX2+/SYN+ cells with foot processes.
(F) Representative image of a PAX2-derived cell inside the glomerulus expressing the podocyte marker WT1 (blue).
(G) Left. Quantification of PAX2+SYN+ cells/glomerular section of all glomeruli in mice with persistent proteinuria (n = 11) and mice
undergoing remission (n = 5). *p < 0.05 versus persistently proteinuric mice (Mann-Whitney test). Right: percentage of glomeruli with
PAX2-derived podocytes inside the glomerular tuft (top) and quantification of PAX2-derived podocytes/glomerular section of positive
glomeruli (bottom).
(H) Percentage of PAX2-derived podocyte over lost podocytes in animals with persistent proteinuria (n = 11) and mice with proteinuria
remission (n = 5).
Data represent the mean ± SEM. DAPI counterstains nuclei. Scale bar represents 20 mm, except in (D) and (E) (10 mm).
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mice with proteinuria remission displayed approximately
ten times more PAX2+cell-derived podocytes than mice
with persistent proteinuria when all glomeruli of the sec-
tions, including those that did not contain PAX2+ cells,
were examined (p < 0.05). However, since glomerular dam-
age is focal and segmental, many of the glomeruli did not
contain PAX2+cell-derived podocytes or show podocyte
depletion. We thus analyzed the percentage of glomeruli
presenting PAX2+cell-derived podocytes within the tuft
and also the number of PAX2+ cells present within these
glomeruli. In the kidney of mice with proteinuria remis-
sion, 15.9% ± 1.9% of glomeruli contained on average
2.58 ± 0.18 PAX2+cell-derived podocytes per glomerular
section (Figure 5G). By contrast, only 3.6% ± 0.7% of
glomeruli contained on average 1.32 ± 0.07 PAX2+cell-
derived podocytes per glomerular section in mice with
persistent proteinuria (Figure 5G).
Taken together, these results demonstrate that remission
or progression of glomerular disorders after podocyte
injury depends upon a balance between an efficient and
dysfunctional differentiation of PAX2+ progenitors into
podocytes.
GSK3 Inhibition Increases RPC Differentiation into
Podocytes throughActivation of RARETranscriptional
Activity
We then used a described in vitro assay to screen a library of
small compounds for their potential to promote human
RPC (hRPC) differentiation into podocytes. This assay is
based on the analysis of levels of expression of podocyte
markers (Ronconi et al., 2009) after exposure to all-trans
retinoic acid (RA), which is known to be a powerful inducer
of hRPC differentiation into podocytes in culture (Peired
et al., 2013). Among the molecules analyzed, we selected
the glycogen synthase kinases 3-a and 3-b (GSK3s) inhibi-
tor BIO (6-bromo-indirubin-30-oxime). Indeed, exposure
of hRPCs to 1 mm BIO strongly enhanced the differentia-
tion process in comparison to RA alone, as demonstrated
by the higher levels of nephrin mRNA and protein
achieved (Figure 6A).We also evaluated the cell-cycle distri-
bution of hRPCs in the presence of BIO. Cell-cycle analysis
of untreated and 1 mM BIO-treated cells after 72 hr
demonstrated that in BIO-treated hRPCs, the percentage
of cells in G0/G1 phase was significantly increased in com-
parison with untreated cells (45% ± 6% versus 76% ± 8%,
p < 0.05; Figure 6B), with a concomitant reduction of the
percentage of cells in S phase of the cell cycle (36.5% ±
5.3% versus 13.7% ± 4.2%, p < 0.05; Figure 6B).
Our observation that GSK3 inhibition synergistically en-
hances RA-induced differentiation suggests that GSK3s
may be directly involved in RA receptor activity. qRT-PCR
for RAR and RXR mRNA in BIO-treated and untreated
hRPCs did not show any difference in expression of RA re-Stem Cceptors (Figure 6C). Because BIO can enhance RA-induced
upregulation of NPHS1 and other podocyte genes acting
on RA response elements (RARE) on their promoters, we in-
fected hRPCs with a RARE-reporter luciferase vector. As ex-
pected, RA treatment induced activity of the RA-responsive
luciferase reporter (Figure 6D), and this effect wasmarkedly
enhanced when hRPCs were treated with RA and 1 mMBIO
(Figure 6D). Thus, GSK3 inhibition promotes hRPC differ-
entiation toward the podocyte lineage by synchronizing
cells in G0/G1 phase of the cell cycle and enhancing
RARE transcriptional activity. To investigate the effect of
GSK3 inhibition on the enhancement of RA transcriptional
activity in vivo, we induced Adriamycin nephropathy in
RARE-lacZ transgenic mice and treated them with BIO
or vehicle (DMSO). As already reported, b-galactosidase
(b-gal) activity was not detected within glomeruli of
healthy kidneys, where only scattered tubules were stained
(Peired et al., 2013). 28 days after induction of podocyte
injury, b-gal activity remained scarce in kidneys of
DMSO-treatedmice, while it appeared in several RPCs iden-
tified as claudin1+ cells lining the Bowman’s capsule or
within the glomerular tuft of BIO-treated mice (Figures 6E
and 6F).
Taken together, these results demonstrate that RPC dif-
ferentiation into podocytes in vitro can be pharmacologi-
cally enhanced by GSK3 inhibition.
Treatment with GSK3 Inhibitors Increases Podocyte
Regeneration and Promotes Glomerular Disease
Remission
To evaluate whether the effects of BIO on RPC differentia-
tion result in an improvement of renal regeneration
following acute podocyte loss in vivo, we induced Adria-
mycin nephropathy in NPHS2.iCreERT2;mT/mG mice, and
when a significant peak in proteinuria was observed
(day 7 starting from the second doxorubicin injection),
we divided the mice into groups exhibiting comparable
proteinuria and started DMSO or BIO treatment. The uri-
nary albumin/creatinine ratio was monitored for the
following 28 days, then animals were sacrificed and kid-
neys harvested for confocal microscopy analysis. The num-
ber of BIO-treated animals with proteinuria decreased after
14 days of BIO treatment and remained significantly lower
than that in the control group at all following time
points (Figure 7A). Representative images of glomeruli of
DMSO- and BIO-treated NPHS2.iCreERT2;mT/mG mice are
shown in Figure 7B. We counted 9.1 ± 0.12 GFP+/SYN+
podocytes per glomerular section in DMSO-treated mice
and 9.5 ± 0.14 GFP+/SYN+ podocytes per glomerular
section in BIO-treated animals (not significant). By
contrast, the number of newly generated podocytes was
statistically different in the two groups of mice. Indeed,
we counted 0.55 ± 0.05 TomRed+/SYN+ podocytes perell Reports j Vol. 5 j 248–263 j August 11, 2015 j ª2015 The Authors 257
Figure 6. GSK3s Inhibition Increases Podocyte Regeneration from PAX2+ Progenitors by Enhancing RA Transcriptional Activity
(A) Effect of BIO treatment on nephrin mRNA (left) and protein (right) expression in hRPCs. Results are expressed as mean ± SEM obtained
in at least four separate experiments. *p < 0.05 by Mann-Whitney test.
(B) Representative cell cycle analysis of untreated- (left) and BIO-treated (right) hRPC. One representative experiment out of four
independent experiments is shown.
(C) Effect of BIO on RAR/RXRmRNA expression in hRPC. Results are expressed as mean ± SEM obtained in at least four separate experiments.
(D) Effect of BIO treatment on the transcriptional activity of RARE-reporter plasmid in hRPCs. Results are expressed as mean ± SEM
obtained in at least four separate experiments *p < 0.05 by Mann-Whitney test.
(E) RARE activity in the glomeruli of RARE-LacZ mice with Adriamycin nephropathy treated with DMSO (left) (n = 6) or BIO (right) (n = 6)
(b-gal, blue; claudin1, red).
(F) Number of b-Gal+/claudin1+ cells lining the Bowman’s capsule or within the glomerular tuft per glomerular section of all glomeruli in
DMSO-treated (n = 6) and BIO-treated mice (n = 6).
*p < 0.05 by Mann-Whitney test. Data represent the mean ± SEM. Scale bar, 20 mm.section in DMSO-treated mice and 0.85 ± 0.03 TomRed+/
SYN+ podocytes per glomerular section in BIO-treated
mice (Figure 7C). These results demonstrate that in
DMSO-treated mice, only 11.6% of the ablated cells had
been replaced, while this percentage increased to 32.6%
in BIO-treated mice (Figure 7D). Similar results were ob-
tained when the kidney tissues were stained with an anti-
WT1 antibody (13.2% in DMSO-treated mice versus
37.3% in BIO-treated mice). Significantly, all eight mice
treated with BIO underwent proteinuria remission, in com-
parison to only two of the DMSO-treated mice (p = 0.007,
c2 test with Fisher’s correction). To evaluate if the increased
podocyte regeneration induced by BIO treatment was
related to an increased differentiation of RPCs into podo-
cytes, the same experiments were repeated in Pax2.rtTA;
TetO.Cre;mT/mG mice. The albumin/creatinine ratio con-
firmed that all BIO-treated mice underwent proteinuria
remission (Figure 7E) associated with a statistically signifi-258 Stem Cell Reports j Vol. 5 j 248–263 j August 11, 2015 j ª2015 The Autcant decrease in BUN levels at day 28 in comparison to
DMSO-treated mice (Figure 7F). Treatment with BIO
reduced glomerulosclerosis in comparison to DMSO treat-
ment (Figure 7G), as evidenced by the reduction in the per-
centage of glomeruli with sclerosis (Figure 7H). Confocal
microscopy clearly demonstrated the presence of a signifi-
cantly higher number of newly generated podocytes
(PAX2+/SYN+ cells) within glomeruli of BIO-treated mice
in comparison to DMSO-treated animals (Figure 7I). In
DMSO-treated mice, the number of green PAX2+/SYN+
cells in the tuft was 0.086 ± 0.01 cells/glomerular section
(Figure 7J), which corresponded to the regeneration of
7% of lost podocytes (Figure 7K). By contrast, in BIO-
treated mice, the number of green PAX2+/SYN+ cells
increased to 0.48 ± 0.06 cells per glomerular section (Fig-
ure 7J), which corresponded to an average regeneration of
32.8% of lost podocytes (Figure 7K). Similar results were
obtained when the kidney tissues were stained with anhors
anti-WT1 antibody (10.3% in DMSO-treated mice versus
35.8% in BIO-treated mice). Significantly, all eight mice
treated with BIO underwent proteinuria remission, in com-
parison to only one of the DMSO-treated mice (p = 0.001,
c2 test with Fisher’s correction). Taken together, these
results demonstrate that differentiation of RPCs into podo-
cytes can be pharmacologically enhanced through treat-
ment with GSK3 inhibitors.DISCUSSION
Determinants of outcome in patients with CKD remain
mostly unknown. Here, we demonstrate that an efficient
generation of novel podocytes by RPCs critically influences
the course of CKD and that RPC differentiation into podo-
cytes can be pharmacologically enhanced for therapeutic
purposes.
Until now, the role of RPCs in glomerular disease was un-
certain, mostly because of the lack of a specific marker to
specifically identify and trace the murine homolog of the
human population (Shankland et al., 2014; Romagnani
et al., 2015). The results of this study show that PAX2,
which is specifically co-expressed with CD133 in human
RPCs (Romagnani et al., 2015), traces the mouse counter-
part of human RPCs within the Bowman’s capsule and
that 8%–10% of total podocytes observed in the adult
mouse kidney are derived from PAX2+ PECs after birth.
These results demonstrate that PAX2+ PECs behave as po-
docyte progenitors, even once glomerular development
has ended, and contribute to the increase of kidney dimen-
sion that is observed during childhood and adolescence. In
adult animals, PAX2+ cells remained mostly localized
within the Bowman’s capsule of subcapsular glomeruli,
but in only 30% of juxtamedullary glomeruli. This is
also in agreement with the observation that the regenera-
tive capacity of these glomeruli is more limited (Ihara
et al., 2010) and that sclerosis initiates and ismore frequent
in juxtamedullary glomeruli (Ikoma et al., 1990).
By using this RPC-specific tracking tool, we could also
establish that RPC differentiation into podocytes can occur
followingglomerular injury and critically contributes to dis-
ease improvement. Previous studies concluded that no po-
docyte turnoveroccursduringagingand followingnephrec-
tomy (Berger et al., 2014), but the role of RPCs was never
explored in models of podocyte injury. Generation of new
podocytes was reported by Wanner et al. once podocyte
depletion was induced through diphtheria toxin injection
(Wanner et al., 2014), but the authors could not establish
from where these new podocytes were derived or whether
theycould influence thecourseof thedisease.Toprovidean-
swers to these questions, in this study, we induced podocyte
depletion by doxorubicin treatment. Adriamycin nephrop-Stem Cathy mimics human FSGS and can exhibit a variable
outcome over time, which is consistent with what happens
in patients. Indeed, even if they are affected by the same dis-
order, somemice develop a persistent proteinuria andCKD,
while others show a peak of proteinuria that is followed by
proteinuria remission, maintenance of kidney function,
and disease resolution (Peired et al., 2013).
To establish whether replacement of lost podocytes by
RPCs could influence CKD outcome, we traced podocyte
regeneration to compare mice that underwent proteinuria
remission with those that developed persistent proteinuria
and CKD using two different lineage-tracing strategies.
By tracking podocytes or RPCs, we consistently observed
that proteinuria remission was associated with regenera-
tion by RPCs of 5%–10% of total kidney podocytes. Since
nephrotic syndrome in these mice caused a 15%–20%
podocyte loss, this corresponds to regeneration of approx-
imately one-third of lost podocytes. By contrast, in mice
that developed persistent proteinuria and CKD, podocyte
regeneration was irrelevant. The Pax2.rtTA;TetO.Cre;mT/
mG model also allowed us to establish that RPCs are the
source of podocyte regeneration after injury. Indeed, in
mice that underwent proteinuria remission after injury,
30% of lost podocytes were replaced by new podocytes
generated by PAX2+ cells. By contrast, the percentage
of PAX2+cell-derived podocytes was irrelevant in mice
with persistent proteinuria. The virtually identical results
observed once the same experimental strategy was
established in Pax2.rtTA;TetO.Cre;mT/mG as well as in
NPHS2.iCreERT2;mT/mG mice demonstrates that RPCs are
the source of podocyte regeneration.
From pathology studies in transplanted patients, we
know that an increase of 20% of podocyte mass can effi-
ciently compensate a reduction of 50% of filtration surface
(Song et al., 2014). Thus, the amount of podocyte replace-
ment that can be provided by RPCs represents a substantial
possibility of recovery that can critically determine the
outcome of a glomerular disorder. Consistently, we know
that the glomerulus can recover from up to a 20% reduc-
tion in podocyte density occurring over a short period of
time (Wiggins, 2007). By contrast, as >30% podocyte
depletion occurs, glomerular stress and further podocyte
depletion supervene, triggering glomerulosclerosis and
ESRD (Fukuda et al., 2012).
Taken together, these results demonstrate that when
RPCs acquire phenotypic and functional features of fully
differentiated podocytes, proteinuria remission occurs,
while when progenitor differentiation is not effective, pro-
teinuria persists and glomerular scars emerge. The pivotal
role played by PECs in the pathogenesis of intraglomerular
scars in FSGS was recently suggested by several studies
(Shankland et al., 2014; Smeets et al., 2009; Lasagni and
Romagnani, 2010). The results of this study demonstrateell Reports j Vol. 5 j 248–263 j August 11, 2015 j ª2015 The Authors 259
Figure 7. GSK3s Inhibition Induces Remission of Glomerular Disease and Is Associated with the Generation of Novel Podocytes
(A) Albumin/creatinine levels in DMSO- (n = 8) and BIO-treated (n = 8) NPHS2.iCreERT2;mT/mG mice with Adriamycin nephropathy; day 0
corresponds to the time of second doxorubicin injection. **p < 0.001 by Mann-Whitney test (day 35).
(B) Kidney of DMSO- (left) and BIO-treated (right) NPHS2.iCreERT2;mT/mG mice stained with anti-SYN (blue).
(C) Number of newly generated podocytes per glomerular section of all glomeruli in healthy (n = 4), DMSO-treated (n = 8), and BIO-treated
(n = 8) mice. *p < 0.05 versus healthy and DMSO-treated mice by Mann-Whitney test.
(D) Percentage of regenerated podocytes over lost podocytes (n = 8 for DMSO-treated and n = 8 for BIO-treated mice).
(E) Albumin/creatinine levels in DMSO- (n = 8) and BIO-treated (n = 8) Pax2.rtTA;TetO.Cre;mT/mG mice with Adriamycin nephropathy;
day 0 corresponds to the time of second doxorubicin injection. **p < 0.001 (day 35) by Mann-Whitney test.
(F) Blood urea nitrogen levels in DMSO- (n = 8), and BIO- (n = 8) treated mice at day 28; *p < 0.05 versus BIO-treated mice by Mann-
Whitney test.
(G) Representative periodic acid-Schiff staining of renal sections of DMSO- (left) and BIO-treated (right) mice.
(legend continued on next page)
260 Stem Cell Reports j Vol. 5 j 248–263 j August 11, 2015 j ª2015 The Authors
that glomerular scars are caused by an inefficient dif-
ferentiation into mature podocytes of those PECs that
represent RPCs. Based on this observation, we reasoned
that RPCs may represent a therapeutic target and that
enhancing RPC differentiation into podocytes could
reduce formation of glomerular scars and promote podo-
cyte regeneration and proteinuria remission. To evaluate
if enhancement of RPC differentiation into podocytes
may represent an attractive therapeutic strategy to pro-
mote remission of glomerular disorders, we screened a li-
brary of small molecules for their potential to promote
RPC differentiation into podocytes. Among the molecules
analyzed, we identified the GSK3 inhibitor BIO as a strong
promoter of hRPC differentiation toward podocytes
in vitro and in vivo. We also demonstrated that BIO acts
by increasing RA binding to its specific RARE elements
and by enhancing RPC sensitivity to the differentiation
effect of endogenously produced RA. Indeed, RA is a podo-
cyte differentiation factor that is released within the Bow-
man’s space following glomerular injury (Peired et al.,
2013). Interestingly, it was previously shown that albu-
minuria sequesters RA within the Bowman’s space and
administration of RA reduces proteinuria in mice with
Adriamycin nephropathy (Peired et al., 2013). However,
doses of RA that are toxic in humans are needed to rescue
the effects of albuminuria (Tallman et al., 2000). Enhance-
ment of RPC differentiation into podocytes by using BIO
avoided toxicity and significantly improved the disease
outcome. This observation demonstrates that the course
of CKD can be shifted from progression to remission by
acting on the RPC response to injury.
Several previous studies support the possibility that RPC
differentiation into podocytes may be involved in remis-
sion of different types of diseases, including proliferative
glomerulonephritis (Rizzo et al., 2013), gestational pre-
eclampsia (Penning et al., 2014), and diabetic nephropa-
thy (Pichaiwong et al., 2013). In addition, drugs that
are already used in clinical practice to delay disease pro-
gression, such as renin-angiotensin-aldosterone system
blockers, not only prevent progressive renal damage but
also promote the regression of glomerulosclerosis in
several models of CKD (Remuzzi et al., 2006), suggesting(H) Percentage of glomeruli with sclerosis in DMSO- (n = 8) and BIO-t
Whitney test.
(I) Top: absence of PAX2+ (green) cells in the majority of glomeruli of
(green) cells expressing SYN (blue) inside the glomeruli in DMSO-treat
of PAX2+ cells inside the glomeruli in BIO-treated Pax2.rtTA;TetO.Cre;m
(blue) (right).
(J) Quantification of PAX2+/SYN+ cells per glomerular section of all g
(n = 8) mice. *p < 0.05 versus healthy and DMSO-treated mice.
(K) Percentage of PAX2-derived podocytes over lost podocytes (n = 8
Data represent the mean ± SEM. DAPI counterstains nuclei. Scale bar
Stem Cthat they may also exert their beneficial effects by promot-
ing RPC differentiation into podocytes (Benigni et al.,
2011). In addition, leptin replacement promotes disease
regression in animal models of advanced diabetic ne-
phropathy by increasing podocyte number, another effect
that may reasonably be mediated by podocyte regenera-
tion provided by RPCs (Pichaiwong et al., 2013). Further
studies are necessary to verify these points. However, the
observation that an efficient differentiation of RPCs into
podocytes determines the outcome of glomerular disorders
and that this process can be pharmacologically enhanced
has important implications for the treatment of patients
with CKD.EXPERIMENTAL PROCEDURES
NPHS2.iCreERT2;mT/mG Mice
NPHS2.iCreERT2 mice were a kind gift from Dr. Farhad Danesh
(Bayor College of Medicine, Houston TX, USA), and B6.129(Cg)-
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J (here abbreviated mT/
mG) mice were purchased from Jackson Laboratory. Double-trans-
genic mice were obtained by crossing the two lines on a 100%
C57Bl/6 background. For information on genotyping, induction




Pax2.rtTA;TetO.Cre;mT/mG mice or Pax2.rtTA;TetO.Cre;R26.
Confetti mice were developed by crossing the mT/mG reporter
strain B6.129(Cg)-Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J or
the Confetti strain Gt(ROSA)26Sortm1(CAG-Brainbow2.1)Cle/J with
the TetO.Cre strain B6.Cg-Tg(TetO-Cre)1Jaw/J, both purchased
from Jackson Laboratory. Double-transgenic mice were then
crossed with Pax2.rtTA mice (Burger et al., 2011) to obtain a
triple-transgenic inducible mouse model with a 100% C57Bl/6
background (Figures S1A and S2A). For information on genotyp-
ing, induction procedures, and tissue processing, see Supplemental
Experimental Procedures.
Adriamycin Nephropathy and BIO Treatment
Adriamycin nephropathy and BIO treatment are detailed in Sup-
plemental Experimental Procedures.reated (n = 8) mice. *p < 0.05 versus DMSO-treated mice, by Mann-
DMSO-treated Pax2.rtTA;TetO.Cre;mT/mG mice (left) and rare PAX2+
ed Pax2.rtTA;TetO.Cre;mT/mGmice (right). Bottom: a higher number
T/mGmouse (left) and PAX2+ cells inside the glomeruli express SYN
lomeruli in healthy (n = 4), DMSO-treated (n = 8), and BIO-treated
for DMSO- and n = 8 for BIO-treated mice).
, 20 mm.
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Immunofluorescence and Confocal Microscopy
Confocal microscopy was performed on 10-mm sections of renal
frozen tissues or on cells by using a Leica SP5 AOBS confocalmicro-
scope (Leica) equipped with a Chameleon Ultra-II two-photon
laser (Coherent). Detailed procedures are reported in Supplemental
Experimental Procedures.
Podocyte Quantification
For quantitation of podocytes in NPHS2.iCreERT2;mT/mG mice,
the number of podocytes (green cells positively stained with SYN
or WT1) and newly generated podocytes (red cells positively
stained with SYN or WT1) per glomerular section was evaluated
in at least 50 glomeruli of at least four sections for each mouse
by two independent observers. Similarly, in Pax2.rtTA;TetO.Cre;
mT/mG mice, the number of new podocytes generated by PAX2+
renal progenitors was evaluated by counting the number of green
cells positively stained with SYN orWT1 per glomerular section in
at least 50 glomeruli of at least four sections for eachmouse by two
independent observers. For detailed calculations, see Supple-
mental Experimental Procedures.
hRPC Cultures and In Vitro Differentiation
For podocyte differentiation and evaluation of BIO effects, cells
were treated for 48 hr with DMEM-F12 (Sigma-Aldrich) supple-
mented with 10% fetal bovine serum (FBS) (Hyclone, from Euro-
clone) and 100 mM RA (Sigma-Aldrich) in the presence or absence
of 1 mM BIO. The expression of nephrin at the mRNA level was
evaluated by real-time qRT-PCR, and the expression of nephrin
at protein levels was evaluated by immunofluorescence. Proce-
dures for small-compound library screening, cell-cycle analysis,
real-time qRT-PCR, and hRPC infection are detailed in Supple-
mental Experimental Procedures.
Study Approval
Animal experiments were approved by the institutional review
board and performed in accordance with institutional, regional,
and state guidelines and in adherence to the NIH’s Guide for the
Care and Use of Laboratory Animals. Mice were housed in a specific-
pathogen-free facility with free access to chow and water and a
12 hr day/night cycle. hRPCswere obtained as previously described
(Sagrinati et al., 2006; Ronconi et al., 2009) in agreement with the
ethics committee onhuman experimentation of the AziendaOspe-
daliero-UniversitariaCareggi, Florence, Italy. Informedconsentwas
obtained from each patient involved in the study.
Statistics
The results are expressed as mean ± SEM. Comparison between
groups was performed by the Mann-Whitney test, the Wilcoxon
test, or ANOVA for multiple comparisons (repeated measures)
with Bonferroni post hoc analysis. Frequencies were compared
by c2 test with Fisher’s correction when appropriate. p < 0.05
was considered to be statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, two figures, and one movie and can be found262 Stem Cell Reports j Vol. 5 j 248–263 j August 11, 2015 j ª2015 The Autwith this article online at http://dx.doi.org/10.1016/j.stemcr.
2015.07.003.
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